{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:36:40Z","timestamp":1793947000428,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-023-03155-z","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T17:30:50Z","timestamp":1682098250000},"page":"2911-2921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Morbimortality after 1321 consecutive CRS\u2009+\u2009HIPEC procedures: seeking excellence in surgery for peritoneal surface malignancy"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-0002","authenticated-orcid":false,"given":"Maria Isabel","family":"Ramos Bernad\u00f3","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2819-1625","authenticated-orcid":false,"given":"Oriol","family":"Crusellas Ma\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3416-1676","authenticated-orcid":false,"given":"Montserrat","family":"Mart\u00edn-Baranera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4929-4241","authenticated-orcid":false,"given":"Pedro","family":"Barrios S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"issue":"2","key":"3155_CR1","first-page":"256","volume":"40","author":"JD Spratt","year":"1980","unstructured":"Spratt JD, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256\u201360.","journal-title":"Cancer Res"},{"key":"3155_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.critrevonc.2016.01.017","volume":"100","author":"D Baratti","year":"2016","unstructured":"Baratti D, Kusamura S, Pietrantonio F, Guaglio M, Niger M, Deraco M. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010\u20132015. A systematic review. Crit Rev Oncol Hematol. 2016;100:209\u201322. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.01.017.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3155_CR3","doi-asserted-by":"publisher","first-page":"5608","DOI":"10.1002\/cncr.25356","volume":"116","author":"O Glehen","year":"2010","unstructured":"Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, on behalf of the French Surgical Association, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients. Cancer. 2010;116:5608\u201318. https:\/\/doi.org\/10.1002\/cncr.25356.","journal-title":"Cancer"},{"key":"3155_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/sla.0b013e3181a45d86","volume":"249","author":"TC Chua","year":"2009","unstructured":"Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg. 2009;249:900\u20137. https:\/\/doi.org\/10.1097\/sla.0b013e3181a45d86.","journal-title":"Ann Surg"},{"issue":"1","key":"3155_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1245\/s10434-018-6992-6","volume":"26","author":"P Piso","year":"2019","unstructured":"Piso P, Nedelcut SD, Rau B, K\u00f6nigsrainer A, Glockzin G, Str\u00f6hlein MA, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26(1):148\u201354. https:\/\/doi.org\/10.1245\/s10434-018-6992-6.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3155_CR6","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1245\/s10434-013-3223-z","volume":"21","author":"EK Bartlett","year":"2014","unstructured":"Bartlett EK, Meise C, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database. Ann Surg Oncol. 2014;21(5):1494\u2013500. https:\/\/doi.org\/10.1245\/s10434-013-3223-z.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"3155_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/SLA.0000000000004326","volume":"272","author":"B Noiret","year":"2020","unstructured":"Noiret B, Clement G, Lenne X, Bruandet A, Glehen O, Voron T, et al. Centralization and oncologic training reduce postoperative morbidity and failure-to-rescue rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: Study on a 10-year National French Practice. Ann Surg. 2020;272(5):847\u201354. https:\/\/doi.org\/10.1097\/SLA.0000000000004326.","journal-title":"Ann Surg"},{"issue":"23","key":"3155_CR8","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.3390\/cancers14235824","volume":"14","author":"F Carboni","year":"2022","unstructured":"Carboni F, Valle M, Vaira M, Sammartino P, Federici O, Robella M, et al. Complications and mortality rate of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Italian peritoneal surface malignancies oncoteam results analysis. Cancers (Basel). 2022;14(23):5824. https:\/\/doi.org\/10.3390\/cancers14235824.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3155_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6847","volume":"2","author":"JM Foster","year":"2019","unstructured":"Foster JM, Sleightholm R, Patel A, Shostrom V, Hall B, Neilsen B, et al. Morbidity and mortality rates following cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy compared with other high-risk surgical oncology procedures. JAMA Netw Open. 2019;2(1): e186847. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.6847.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3155_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00268-014-2801-y","volume":"39","author":"AM Kuijpers","year":"2015","unstructured":"Kuijpers AM, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Ramshorst B, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg. 2015;39(2):453\u201360. https:\/\/doi.org\/10.1007\/s00268-014-2801-y.","journal-title":"World J Surg"},{"issue":"1","key":"3155_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1245\/s10434-006-9185-7","volume":"14","author":"J Esquivel","year":"2007","unstructured":"Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. 2007;14(1):128\u201333. https:\/\/doi.org\/10.1245\/s10434-006-9185-7. (Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S334-5).","journal-title":"Ann Surg Oncol"},{"key":"3155_CR12","unstructured":"Barrios P, Roqu\u00e9 M, Lozano JM, Ramos I, Bianchi A, Bonfill X. Revisi\u00f3n sistem\u00e1tica del tratamiento combinado multidisciplinar en las enfermedades malignas del peritoneo. Citorreducci\u00f3n quir\u00fargica radical + quimioterapia intraperitoneal +\/- hipertermia (t\u00e9cnica de Sugarbaker). Informes de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias, AATRM n\u00fam. 2007\/19."},{"key":"3155_CR13","unstructured":"Barrios P, Ramos I, Escayola C, Martin M. Implementaci\u00f3n y desarrollo de un programa de tratamiento de la carcinomatosis peritoneal en Catalu\u00f1a. Indicaciones y resultados cl\u00ednicos con la t\u00e9cnica de Sugarbaker. Barcelona: Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologia i Recerca M\u00e8diques. Servei Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya; 2009."},{"key":"3155_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"PH Sugarbaker","year":"1995","unstructured":"Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29\u201342. https:\/\/doi.org\/10.1097\/00000658-199501000-00004.","journal-title":"Ann Surg"},{"key":"3155_CR15","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res"},{"issue":"12","key":"3155_CR16","doi-asserted-by":"publisher","first-page":"7784","DOI":"10.1245\/s10434-021-09842-x","volume":"28","author":"P Barrios","year":"2021","unstructured":"Barrios P, Ramos I, Crusellas O, Sabia D, Mompart S, Bijelic L. Safe anastomoses without ostomies in cytoreductive surgery with heated intraperitoneal chemotherapy: technical considerations and modifications. Ann Surg Oncol. 2021;28(12):7784\u201392. https:\/\/doi.org\/10.1245\/s10434-021-09842-x.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3155_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.soc.2018.02.009","volume":"27","author":"S Kusamura","year":"2018","unstructured":"Kusamura S, Gonz\u00e1lez-Moreno S, Nizri E, Baratti D, Guadagni S, Guaglio M, et al. Learning curve, training program, and monitorization of surgical performance of peritoneal surface malignancies centers. Surg Oncol Clin N Am. 2018;27(3):507\u201317. https:\/\/doi.org\/10.1016\/j.soc.2018.02.009.","journal-title":"Surg Oncol Clin N Am"},{"key":"3155_CR18","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1245\/s10434-014-3975-0","volume":"22","author":"EK Bartlett","year":"2015","unstructured":"Bartlett EK, Choudhury RA, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Intraperitoneal chemotherapy at the time of surgery is not associated with increased 30-day morbidity and mortality following colorectal resection. Ann Surg Oncol. 2015;22:1664\u201372. https:\/\/doi.org\/10.1245\/s10434-014-3975-0.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"3155_CR19","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1245\/s10434-020-09301-z","volume":"28","author":"L \u00dcberr\u00fcck","year":"2021","unstructured":"\u00dcberr\u00fcck L, Nadiradze G, Yurttas C, K\u00f6nigsrainer A, K\u00f6nigsrainer I, Horvath P. In-hospital mortality and complication rates according to health insurance data in patients undergoing hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies in Germany. Ann Surg Oncol. 2021;28(7):3823\u201330. https:\/\/doi.org\/10.1245\/s10434-020-09301-z.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"3155_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/jso.26371","volume":"123","author":"A Nikiforchin","year":"2021","unstructured":"Nikiforchin A, Gushchin V, King MC, Baron E, Nieroda C, Sittig M, et al. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience. J Surg Oncol. 2021;123(4):1030\u201344. https:\/\/doi.org\/10.1002\/jso.26371.","journal-title":"J Surg Oncol"},{"issue":"3","key":"3155_CR21","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.amjsurg.2019.09.017","volume":"219","author":"EW Beal","year":"2020","unstructured":"Beal EW, Ahmed A, Grotz T, Leiting J, Fournier KF, Lee AJ, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478\u201383. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.09.017.","journal-title":"Am J Surg"},{"key":"3155_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1245\/s10434-015-4674-1","volume":"23","author":"AN Doud","year":"2016","unstructured":"Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI. Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:503\u201310. https:\/\/doi.org\/10.1245\/s10434-015-4674-1.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"3155_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ejso.2017.01.015","volume":"43","author":"JB Delhorme","year":"2017","unstructured":"Delhorme JB, Sattler L, Severac F, Triki E, Gross I, Romain B, et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor? Eur J Surg Oncol. 2017;43(6):1095\u2013101. https:\/\/doi.org\/10.1016\/j.ejso.2017.01.015.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"3155_CR24","doi-asserted-by":"publisher","first-page":"e0261852","DOI":"10.1371\/journal.pone.0261852","volume":"16","author":"O Sand","year":"2021","unstructured":"Sand O, Andersson M, Arakelian E, Cashin P, Semenas E, Graf W. Severe pulmonary complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are common and contribute to decreased overall survival. PLoS ONE. 2021;16(12):e0261852. https:\/\/doi.org\/10.1371\/journal.pone.0261852.","journal-title":"PLoS ONE"},{"key":"3155_CR25","doi-asserted-by":"publisher","first-page":"635314","DOI":"10.1155\/2012\/635314","volume":"2012","author":"V Preti","year":"2012","unstructured":"Preti V, Chang D, Sugarbaker PH. Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract. 2012;2012:635314. https:\/\/doi.org\/10.1155\/2012\/635314.","journal-title":"Gastroenterol Res Pract"},{"issue":"6","key":"3155_CR26","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s12094-019-02195-8","volume":"22","author":"P Cascales Campos","year":"2020","unstructured":"Cascales Campos P, Martinez Insfran LA, Wallace D, Gil J, Gil E, Gonzalez Gil A, et al. Identifying the incidence of respiratory complications following diaphragmatic cytoreduction and hyperthermic intraoperative intraperitoneal chemotherapy. Clin Transl Oncol. 2020;22(6):852\u20139. https:\/\/doi.org\/10.1007\/s12094-019-02195-8.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"3155_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11605-019-04463-y","volume":"24","author":"TC Lee","year":"2020","unstructured":"Lee TC, Wima K, Sussman JJ, Ahmad SA, Cloyd JM, Ahmed A, et al. Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a US HIPEC collaborative study. J Gastrointest Surg. 2020;24(1):165\u201376. https:\/\/doi.org\/10.1007\/s11605-019-04463-y.","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"3155_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1245\/s10434-021-10642-6","volume":"29","author":"A Garc\u00eda-Fadrique","year":"2022","unstructured":"Garc\u00eda-Fadrique A, Estevan Estevan R, Sabater OL. Quality standards for surgery of colorectal peritoneal metastasis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2022;29(1):188\u2013202. https:\/\/doi.org\/10.1245\/s10434-021-10642-6.","journal-title":"Ann Surg Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03155-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03155-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:22:52Z","timestamp":1693210972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03155-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,21]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["3155"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03155-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,21]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study has been performed in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments. The study was approved by the local IRB at the beginning of the Program.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}